The development comes weeks after rival Pfizer Inc and its German partner BioNTech SE sought full approval for their COVID-19 vaccine in the United States.
Moderna said it will continue to submit data to the US Food and Drug Administration on a rolling basis over the coming weeks with a request for a priority review.
Moderna Inc, whose vaccine is authorized for adults 18 and older, said it will submit the findings of its adolescent study to the US Food and Drug Administration and other regulators for emergency use authorization in early June.
US regulators took about a month to review a similar study from Pfizer/BioNtech, which was authorized for ages 12-15 on May 10. If Moderna gets the same treatment, its authorization would come in early July.
Tourism might get a shot in the arm from the European Union, which said it was "fully on track" to ensure a Covid health pass would be ready in June to boost travel.